Last reviewed: June 17, 2026 Last updated: June 17, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
El estudio, publicado en Cell Metabolism , utiliza un modelo experimental basado en la administracin de la semaglutida en ratones, y muestra cmo un tratamiento con estos medicamentos lleva a un descenso de la capacidad de generar fuerza , alrededor del 20%, un porcentaje desproporcionado en relacin con la prdida de masa muscular, notablemente inferior
This potentially leads to limitations in GLP-1 receptor agonist use in patients who are unwilling or unable to administer these medications subcutaneously
Clin Cancer research: an Off J Am Assoc Cancer Res (2017) 23(8):208192
SidahmedECornellierMLRenJAskew LM LiYTalaatNet al
Medium chain triglycerides modulate the ketogenic effect of a metabolic switch
